Impaired myocardial flow reserve (MFR) has been demonstrated in hypertension, and has been associated with peripheral vascular changes. We investigated whether MFR was impaired and associated with structural and/or functional vascular changes in hypertensive patients without evidence of coronary artery disease (CAD). We measured left ventricular (LV) mass index by echocardiography and MFR by positron emission tomography in 33 unmedicated, hypertensive patients with electrocardiographic LV hypertrophy without CAD, and 15 age-and gender-matched normotensive subjects. We also measured 24-h ambulatory blood pressure, minimal forearm vascular resistance (MFVR) by plethysmography, media:lumen ratio in isolated, subcutaneous resistance arteries by myography, intima-media crosssectional area of the common carotid artery, and flow-mediated (FMD) and nitroglycerin-induced dilatation (NID) of the brachial artery by ultrasound. Compared to the controls, the patients had impaired MFR (2.4 (95% CI 1.95-2.8) vs 3.4 (2.7-4.2), Po0.01) due to increased resting myocardial blood flow (MBF) (0.82 (0.73-0.91) vs 0.65 (0.56-0.75) ml/g min), and decreased dipyridamole-stimulated MBF (1.80 (1.55-2.1) vs 2.3 (1.80-2.8) ml/g min, both Po0.05). The difference in resting MBF disappeared (80 (74-87) vs 86 (74-97) ll/ kg mmHg, NS) when normalized for blood pressure and heart rate. MFR correlated negatively to median 24-h systolic blood pressure (r ¼ À0.50, Po0.01) as well as to LV mass index (r ¼ À0.45, Po0.05) and MFVR in men (r ¼ À0.47, Po0.05), and positively to FMD (r ¼ 0.44, Po0.05) and NID (r ¼ 0.40, Po0.05). Hypertensive patients with electrocardiographic LV hypertrophy without CAD had impaired MFR associated with cardiovascular hypertrophy and vasodilatory dysfunction. This suggests that MFR is impaired by LV hypertrophy and structural/functional vascular damage in the coronary and noncoronary circulation.
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Introduction
Left ventricular (LV) hypertrophy is an independent risk factor for cardiovascular morbidity and mortality in hypertension. 1 Ischaemia due to impaired myocardial flow reserve (MFR) has been demonstrated in patients with hypertension, 2 and could contribute to the increased morbidity and mortality. 3 In hypertensive patients with LV hypertrophy, impaired MFR has been attributed to increased resting myocardial blood flow (MBF) due to a higher cardiac workload. 4 However, other mechanisms, such as reduced capillary density in the hypertrophied myocardium and impairment of coronary artery dilatation due to structural vascular remodelling and/or endothelial dysfunction may also contribute to reduced MFR in hypertension. medium-sized conduit arteries 8 and in resistance arteries. 9, 10 Nonhypertensive patients with symptoms of angina pectoris, but with normal coronary angiograms, have decreased flow-mediated dilatation (FMD) in the brachial artery during reactive hyperaemia, 11 as well as increased minimal forearm vascular resistance (FVR), 12 suggesting parallel vascular dysfunction in the coronary and peripheral vasculature. This parallel vascular dysfunction has also been identified by Leschke et al, 13 who found increased minimal FVR in hypertensive patients with reduced MFR.
The aim of this study was to investigate whether hypertensive patients without coronary artery disease (CAD) had impaired MFR evaluated by positron emission tomography, and whether impaired MFR was related to LV hypertrophy and vascular structure and dysfunction in a selected high-risk group of patients with hypertension and electrocardiographic LV hypertrophy.
Methods

Subjects
We studied 33 patients (27 men and 6 women), age 56-76 (mean 6576) years, with essential hypertension (systolic blood pressure 173 (95% CI 169-177) and diastolic blood pressure 95 (92-98)) after 1-2 weeks of placebo treatment. They had LV hypertrophy determined by screening electrocardiogram prior to study entry. All patients were participants in the Insulin Carotids US Scandinavia (ICARUS) substudy 14 of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, and met the inclusion and exclusion criteria of the study as previously described. 15 There were 8 smokers, 16 exsmokers, and nine nonsmokers. The mean duration of known hypertension was 8 years and 4 months, ranging from 0 to 35 years. Eight patients had recently diagnosed hypertension, of whom five had never received antihypertensive treatment. Three patients had been previously treated with beta-receptor blockers or diuretics alone, and 25 had received calcium antagonists, angiotensin converting enzyme inhibitors, or angiotensin II receptor blockers before the placebo period. Glucose intolerance was found in 10 patients, and 12 patients had diabetes according to World Health Organization criteria. 16 None of the patients received lipid-lowering treatment.
MFR was measured in 15 healthy, age-and gender-matched controls (12 men and three women). Other characteristics of both groups are listed in Tables 1 and 2 .
Protocol and methods
Ultrasound of the common carotid arteries Intima-media thickness (IMT) and the lumen diameter of the common carotid arteries were measured by ultrasound using the ACUSON 128XP/10c (Acuson Corporation, CA, USA) and a linear 7 MHz transducer. IMT of the common carotid arteries was measured in the 1 cm segment proximal to the dilation of the carotid bulb as described by Howard et al 17 in the ARIC study. The longitudinal B-mode image was accepted as valid when a double line representing lumen-intima and media-adventitia interfaces was visualized in the longest possible segment of the near and far walls. At end-diastole, IMTs of the far walls of the left as well as of the right common carotid arteries were measured at 10 points, 1 mm apart, using the leading-edge convention, and the mean value was calculated. Based on end-diastolic IMT and lumen diameter, the crosssectional area of the intima-media complex (IMA) was calculated and indexed by the height, because lumen diameter, and therefore IMA, were more closely related to height than to body surface area. 
Plethysmography of the forearm
The maximal forearm blood flow was measured after 10 min of ischaemia 18 using strain-gauge plethysmography (Model EC5R, Hokanson, Inc., Bellevue, WA, USA). 19 A wrist-occluding cuff was used. Forearm blood flow was measured for 3 s every 6 s during the first minute of hyperaemia, and was expressed as ml per 100 ml tissue per minute. At the same time, blood pressure was measured three times with a semiautomatic sphygmomanometer (Dinamap 1846 SX, Critikon, Johnson & Johnson Medical, Inc., USA). FVR was calculated as the mean blood pressure divided by corresponding forearm blood flow, and the lowest value was chosen to represent the minimal FVR. We chose to analyse minimal FVR in men and women separately 14 because minimal FVR values and standard deviations were higher in the relatively obese women (3.171.42 vs 2.370.48 mmHg min 100), probably due to a lower percent muscle tissue in their forearms. 20 Echocardiography Echocardiograms were performed following a standardized protocol employed in other multicentre studies. 21 Examinations included two-dimensional (2-D) guided M-mode echocardiograms and selected 2-D recordings. The examinations were performed with an echocardiograph (VingMed CFM-800, General Electric) equipped with 3.0-3.5 and 2.0-2.5 MHz probes and Super-VHS video recorder. Echocardiograms were centrally read using computerized review stations (Digisonics, Inc., Houston, TX, USA) at the Reading Center in New York by experienced physicians blinded to clinical information. LV dimensions were measured according to recommendations of the American Society of Echocardiography. When optimal orientation of the LV or atrial M-mode views could not be obtained, correctly oriented 2-D linear dimension measurements were made using parasternal views by the leadingedge convention. End-diastolic LV dimension and wall thickness were used to calculate LV mass by a validated formula that gives values closely related to autopsy LV weight (r ¼ 0.90) and that have shown excellent reproducibility. 21 LV hypertrophy was defined as LV mass index X104 g/m 2 for women and 116 g/m 2 for men.
Myography of subcutaneous resistance arteries
Under local anaesthesia, a subcutaneous biopsy measuring about 1 cm 3 was taken from the gluteal region. The biopsy was placed in a cold physiological saline solution. The small resistance arteries (100-500 mm) were isolated under microscope and mounted on a myograph (Automated Dual Wire Myograph System 500A, J. P. Trading I/S, Å rhus, Denmark). The thickness of the different layers and lumen were measured, and the vessels were normalized to 100 mmHg distension pressure 22 for calculation of media:lumen ratio of the subcutaneous resistance arteries. In most patients, media: lumen ratio represented the mean of two resistance arteries. All vessels were exposed to cumulatively increasing concentrations of norepinephrine until maximal constriction. The concentrations giving between 80 and 100% of maximal constriction were chosen as preconstrictors in the following. After submaximal preconstriction with norepinephrine, acetylcholine was added in cumulatively increasing amounts until maximal relaxation. After washout of acetylcholine and submaximal preconstriction with norepinephrine, nitroprusside was added in cumulatively increasing concentrations until maximal relaxation. The maximal relative dilatation and the sensitivity assessed as the negative logarithm of the concentration leading to 50% of maximal effect were calculated using the GraphPad Prism.
Ambulatory blood pressure
After the patient rested for 1 h, an automatic blood pressure device that measured ambulatory blood pressure using the cuff-oscillometric method (Takeda TM-2421, A&D Co. Ltd, Tokyo, Japan) 23 was applied to the left arm and worn for 24 h. Oscillometric blood pressures were measured every 30 min during daytime and every hour during night time (2300 to 600 hours). There were more than 20 readable measurements during 24 h in 29 patients, considered sufficient 24 to calculate the median values for 24-h blood pressures. Owing to relative few measurements in some of the patients, we have used median values, which are more resistant to influence of outliers.
Positron emission tomography
All subjects were studied on a whole-body tomograph (PC 4096, General Electric Medical Systems, Milwaukee, WI, USA) with eight crystal rings forming 15 2-D imaging planes spaced by 6.5 mm, and an intrinsic spatial resolution of 6-8 mm fullwidth at half-maximum (FWHM). 25 Corrections for dead time, attenuation, and scatter were applied, and the images were reconstructed to an effective inplane resolution of 7-mm FWHM using a Hanning filter. All subjects refrained from taking caffeinecontaining food and beverages for at least 18 h prior to the scanning. During the first 2 min after each 13 Nammonia injection, blood pressure and heart rate were recorded two or three times and mean values calculated (Hewlett Packard Component Monitoring System). MBF was measured at rest and after pharmacological stimulation with dipyridamole (0.56 mg/kg over 4 min), applied 7 min before 13 Nammonia infusion. The two perfusion studies were performed in an identical manner separated by a time period of 50-60 min to allow for physical decay of 13 N-ammonia activity. A measure of 700 MBq 13 Nammonia was infused intravenously over 30 s by an infusion pump (Harvard Apparatus, Inc.) and serial images were acquired for 20 min (24 frames: 13 Â 6, 3 Â 12, 3 Â 20, 4 Â 30, and 1 Â 900 s). Immediately after the resting dynamic acquisition sequence, a 5-min correction frame was applied. The 5-min frame was used for residual 13 N-ammonia and background activity correction of the subsequent transmission scan. Transmission data were acquired for 20 min. For each frame of the serially acquired data, sets of 35 transaxial images were reconstructed and were resampled on a workstation (General Electric Medical Systems, Milwaukee, WI, USA) into 12-15 contiguous short-axis slices of the left ventricle. All regions of interest were copied to obtain regional myocardial and arterial time activity curves. Correction for partial volume effects was performed in all subjects with a recovery coefficient function based on the assumption of a one-dimensional Gaussian resolution curve, and taking into account the scanner resolution, the size of the regions of interest, and individual LV wall thickness estimated by echocardiography. The first 2 min of the corrected myocardial time activity curves were then fitted with a previously validated, two-compartment tracer kinetic model. The flow values obtained for the three anatomical regions were finally averaged to one global flow value.
Dipyridamole was used as a vasodilating agent to produce maximal coronary vasodilation. Although some previous studies have suggested that the standard dose of dipyridamole of 0.56 mg/(kg min) may not induce maximal vasodilation 26 and that adenosine may be more effective, 27 this has not been confirmed using PET quantitation. Neither addition of high-dose dipyridamole nor handgrip could further increase myocardial perfusion. 28 Furthermore, comparisons of maximal MBF during adenosine infusion with that of intravenous dipyridamole in normal men revealed no difference using PET. 29 Ultrasound scanning of the brachial artery The internal diameter of the right brachial artery was measured by ultrasound using the ACUSON 128XP/ 10c (Acuson Corporation, CA, USA) and a linear 7 MHz transducer 10-13 cm proximal to the elbow with optimal view of a long linear segment of the brachial artery. The internal diameter in end-diastole was measured in a longitudinal B-mode image as described for IMT measurements. A blood pressure cuff placed just distal to the elbow was inflated to a pressure 40 mmHg above systolic blood pressure for 5 min. The internal diameter was recorded continuously and measured every 10 s from 50 to 120 s after cuff deflation. The maximal postischaemic enddiastolic internal diameter was measured, and FMD, a noninvasive measure of endothelial function, 30 was calculated as the relative increase in diameter (100 * (Diameter hyperaemia ÀDiameter rest )/ Diameter rest ). About 25 min after cuff-deflation nitroglycerin was infused in the left brachial vein at a rate of 1.5 mg/kg min for 10 min, which has been shown to induce maximal dilatation in the radial artery in healthy subjects. 31 During continued infusion, the internal diameter of the brachial artery was measured in end-diastole, and the nitroglycerininduced dilatation (NID) was calculated as the relative increase in diameter. All readings were taken on digitized pictures (Optimas 6.11, Optimas Corporation, USA) at The University of Michigan Medical Center in Ann Arbor.
Statistical analysis
For data management and statistical analyses, the Statistica 5.1 (StatSoft, Inc., Tulsa, OK, USA) was used. Parametric statistics were used to calculate mean values and 95% confidence intervals (in brackets) unless otherwise stated. Differences between patients and controls were analysed using unpaired t-test. We performed simple linear regression analyses calculating the correlation coefficient (r). To find independent correlates of continuous measures, stepwise, backward multiple linear regression analyses calculating the standardized regression coefficient for each parameter (b) and the adjusted coefficient of determination for the model (adj. R 2 ) were performed. Two-tailed P-values o0.05 were considered statistically significant.
Results
MFR was lower in hypertensive patients than in ageand gender-matched normotensive subjects (Table 2 ). This was due to a higher resting MBF in combination with a lower dipyridamole-stimulated MBF in the hypertensive patients (Table 2 ). When normalizing for higher blood pressure and heart rate in the hypertensive patients by dividing MBF by ratepressure product, the difference in resting MBF, but not in dipyridamole-stimulated MBF, disappeared ( Table 2) .
As compared to the 11 patients without echocardiographic LV hypertrophy, the 21 patients with LV hypertrophy had slightly, but not significantly higher, resting MBF, and a significantly lower dipyridamole-stimulated MBF leading to a significantly lower MFR (Table 3) . After normalizing for differences in blood pressure and heart rate, the differences in resting MBF were reduced, while the differences in dipyridamole-stimulated MBF remained unchanged (Table 3) . Comparing the 11 patients without LV hypertrophy on echocardiography with the normotensive subjects, we did not find any significant differences in MBF or MFR, although the patients had higher systolic blood pressure (Po0.001) as well as higher LV mass (Po0.01).
In the hypertensive group, resting MBF was positively correlated to systolic blood pressure (r ¼ 0.71, Po0.001) and to the systolic blood pressure-heart rate product (r ¼ 0.74, Po0.001) at the time of the positron emission tomography. Both with and without blood pressure and heart rate normalization, resting MBF was not significantly correlated to median 24-h systolic blood pressure, LV mass index, intima-media cross-sectional area of the common carotid artery (IMA) indexed by height, minimal FVR, or NID or FMD of the brachial artery (Table 4) .
Among hypertensive patients, dipyridamole-stimulated MBF correlated negatively with LV mass index and positively with NID (Table 4) . MFR correlated negatively to 24-h systolic blood pressure (Figure 1a) , LV mass index, and minimal FVR (Table 4) , and positively to both NID and FMD of the brachial artery (Figure 1b 
Discussion
Hypertensive patients with electrocardiographic LV hypertrophy had, as compared to age-and gendermatched normotensive control subjects, impaired MFR due to increased resting MBF and decreased dipyridamole-stimulated MBF. The difference in resting MBF disappeared with normalization for blood pressure and heart rate, and the difference in dipyridamole-stimulated MBF was primarily in patients with echocardiographic LV hypertrophy. None of the patients showed any signs of coronary artery disease. Reduced MFR was related to LV hypertrophy, peripheral vascular structure, and vasodilatory dysfunction in the brachial artery.
Blood pressure
Resting MBF, which as expected was related to the cardiac workload expressed as the systolic blood pressure-heart rate product at the time of positron emission tomography, was higher in the hypertensive patients compared to the normotensive control subjects as demonstrated previously by Kozàkovà et al, 4 but the difference disappeared with normalization for blood pressure and heart rate. This indicates that higher cardiac workload at rest, and thereby higher resting MBF, contributes to the reduced MFR in patients with hypertension. However, the fairly strong negative correlation between MFR and median 24-h systolic blood pressure found in our study cannot be explained purely by the loadrelated, high resting MBF, because resting MBF did not correlate significantly to median 24-h systolic blood pressure. This is further supported by the fact that patients without echocardiographic LV hypertrophy had preserved MFR although they had higher blood pressures. In our patients, high median 24-h systolic blood pressure was also associated with high IMA/h, high minimal FVR, low NID, and low FMD. 32 Therefore, the findings indicate parallel hypertension-induced structural and functional vascular changes in the noncoronary and coronary arterial trees. These changes in the coronary arteries may compromise early diastolic coronary arterial inflow 33 and thereby contribute to the reduction in MFR. 34 This is further supported by the fact that 24-h blood pressure level and cardiovascular changes did not contribute independently to the variation in MFR.
LV hypertrophy
In patients with echocardiographic LV hypertrophy, dipyridamole-stimulated MBF and MFR were reduced both with and without blood pressure normalization. The reduction was proportional to the degree of LV hypertrophy. This provides an additional mechanism, partially independent of blood pressure, for compromising diastolic coronary arterial inflow 33 leading to reduced MFR. 34 However, in this study this mechanism seems only to be significant in patients with high LV mass, because increased LV mass without LV hypertrophy did not lead to reduced MFR. Whether this reduction in MFR is due to LV hypertrophy per se or reflects its relations to structural/functional vascular changes remains to be investigated, but it may explain why MFR is preserved in uncomplicated hypertension. 35 
Peripheral vascular structure
In hypertensive men, MFR was negatively related to minimal FVR. The maximal hyperemic blood flow in the forearm is dependent on the dilatory capacity of the resistance arteries as well as the crosssectional area of the total vascular bed in the forearm. 7 Increased minimal FVR is, therefore, an indicator of resistance artery remodelling and anatomic microvascular rarefaction resulting in reduced peripheral flow reserve. A direct relationship between coronary and peripheral flow reserve has previously been shown in patients with hypertension 13 as well as in patients with angina-like chest pain and angiographically normal coronary arteries. 12, 36 Media:lumen ratio in the subcutaneous resistance arteries did not correlate significantly with MFR. This difference between minimal FVR and media:lumen ratio of the subcutaneous resistance arteries in relation to MFR may be due to the basic differences between the two methods. Although both minimal FVR and media:lumen ratio reflect vascular remodelling, only MFVR assesses the number of recruitable vessels in the forearm, which may parallel myocardial vessel recruitment. A lack of relation between MFR and media:lumen ratio in subcutaneous resistance arteries has previously been demonstrated in patients with syndrome X. 36 
Vasodilatory dysfunction
We found that low MFR was related to impaired vasodilatory capacity in conduit arteries as indicated by low FMD and low NID in the brachial artery. However, MFR did not relate to endothelial dysfunction in isolated subcutaneous resistance arteries as measured by acetylcholine-induced vasodilatation. Impaired FMD has been demonstrated in patients with microvascular angina and coronary artery disease, 11 and has been related to coronary endothelial dysfunction in patients evaluated for coronary artery disease. 37 Our results extend these findings to hypertensive patients without coronary heart disease, but with LV hypertrophy on electrocardiogram. However, in these patients FMD and NID decreased parallel with increasing blood pressure indicating that the reduced FMD may be due to impaired smooth muscle cells rather than endothelial dysfunction. 32 As it is impossible to separate the mechanisms behind this reduced vasodilatory capacity in the brachial artery, we will refer to it as vasodilatory dysfunction. Therefore, it is likely that the coronary vasodilatory dysfunction in patients with hypertension and electrocardiographic LV hypertrophy is due to coronary artery hypertrophy/ remodelling impairing the vasodilatory capacity. Our study, together with the other studies mentioned, suggests that vasodilatory dysfunction is often generalized offering the possibility to use reduced FMD or NID as indicators of impaired MFR. However, the relationship is rather weak, especially in individuals with high FMD, suggesting that only a very low FMD may be used to predict low MFR. The lack of correlation between MFR and acetylcholine-as well as nitroprusside-induced relaxation in subcutaneous resistance arteries has previously been demonstrated in patients with syndrome X, 36 and may reflect functional differences between the two vascular beds.
As indicated by the relative low correlation coefficient in all the correlations, it is not possible to use any of the vascular parameters as surrogates of MFR in the individual patient; however, FMD or IMT, both of which are noninvasive, may possibly be used as markers of coronary as well as noncoronary vascular damage in large-scale studies in hypertension.
Limitations
Owing to the inclusion criteria of the LIFE study, the patients were highly selected consisting of middleaged and elderly patients with longstanding hypertension and LV hypertrophy without significant ischaemic heart disease. This selection may confound the basic relationships between hypertensive and metabolic abnormalities 14 and might explain why MFR was not related to diabetes or to high serum lipids as expected. 38 
Conclusion
Hypertensive patients with electrocardiographic LV hypertrophy had, compared to age-and gendermatched normotensive control subjects, impaired MFR due to increased resting MBF as a direct consequence of increased haemodynamic load at rest and due to decreased dipyridamole-stimulated MBF. MFR was reduced proportional to the extent of cardiovascular hypertrophy and vasodilatory dysfunction in conduit arteries suggesting that MFR may be impaired by LV hypertrophy as well as by associated structural/functional vascular damage in the coronary and noncoronary circulation.
